Urotensin-II: a novel systemic hypertensive factor in the cat

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):274-80. doi: 10.1007/s00210-004-0873-1. Epub 2004 Feb 19.


Urotensin-II, a potent mammalian vasoconstrictor, may play a role in the etiology of essential hypertension. However, a species suitable for assessing such a role, one where a "classical" systemic hypertensive response (increase in mean blood pressure and systemic vascular resistance) is observed following bolus i.v. urotensin-II administration, has yet to be identified. The present study demonstrates that the cat may represent such a species since urotensin-II potently (pEC(50)s 9.68+/-0.24-8.73+/-0.08) and efficaciously (E(max) 73+/-15%-205+/-21% KCl) constricts all feline isolated arteries studied (aortae, renal, femoral, carotid, and mesenteric conduit/resistance). Accordingly, exogenous urotensin-II (1 nmol/kg, i.v.) effectively doubles both mean blood pressure (from 99+/-14 to 183+/-15 mmHg) and systemic vascular resistance (from 0.36+/-0.12 to 0.86+/-0.20 mmHg/ml/min) in the anaesthetized cat (without altering heart rate or stroke volume). Thus, in view of these profound contractile effects, the cat could be suitable for determining the effects of urotensin-II receptor antagonism on cardiovascular homeostasis in both normal and diseased states.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Cats
  • Dose-Response Relationship, Drug
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / physiopathology
  • In Vitro Techniques
  • Male
  • Urotensins / pharmacology*
  • Urotensins / toxicity
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology


  • Urotensins
  • urotensin II